Better Therapeutics has received marketing authorisation from the US Food and Drug Administration (FDA) for its prescription-only digital behavioural therapeutic device, AspyreRx.
AspyreRx (previously BT-001) is intended for delivering cognitive behavioural therapy to type 2 diabetes (T2D) patients aged 18 years and above.
The authorisation has been granted for the device based on the efficacy and safety data of a randomised controlled study, which assessed 668 participants.
